BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17143936)

  • 1. Colon cancer and the immune system: the role of tumor invading T cells.
    Waldner M; Schimanski CC; Neurath MF
    World J Gastroenterol; 2006 Dec; 12(45):7233-8. PubMed ID: 17143936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
    Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ
    Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
    Zhu S; Lin J; Qiao G; Xu Y; Zou H
    Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer.
    Ma YF; Ren Y; Wu CJ; Zhao XH; Xu H; Wu DZ; Xu J; Zhang XL; Ji Y
    Mol Immunol; 2016 Jul; 75():11-20. PubMed ID: 27209087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
    Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
    Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
    Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
    Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role for CD8+FoxP3+ regulatory T cells in colon cancer immune response in humans.
    Sobhani I; Le Gouvello S
    Gut; 2009 Jun; 58(6):743-4. PubMed ID: 19433592
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors.
    Torcellan T; Hampton HR; Bailey J; Tomura M; Brink R; Chtanova T
    Proc Natl Acad Sci U S A; 2017 May; 114(22):5677-5682. PubMed ID: 28507145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
    Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
    Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
    Badoual C; Hans S; Rodriguez J; Peyrard S; Klein C; Agueznay Nel H; Mosseri V; Laccourreye O; Bruneval P; Fridman WH; Brasnu DF; Tartour E
    Clin Cancer Res; 2006 Jan; 12(2):465-72. PubMed ID: 16428488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.
    Cafri G; Yossef R; Pasetto A; Deniger DC; Lu YC; Parkhurst M; Gartner JJ; Jia L; Ray S; Ngo LT; Jafferji M; Sachs A; Prickett T; Robbins PF; Rosenberg SA
    Nat Commun; 2019 Jan; 10(1):449. PubMed ID: 30683863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.